logo-loader

PreveCeutical Medical announces completion on analgesic program is near

Published: 13:56 23 Jul 2020 BST

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon.

Van Deventer telling Proactive about the program and what the next step will be as they look to develop pain therapies from this program.

PreveCeutical Medical making key advances with its Sol-gel program

Dr Harry Parekh, chief research officer for PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), tells Proactive's Andrew Scott they've hit a number of key milestones with their Sol-gel program. He says they've now successfully optimised the conditions for extracting cannabinoids from one...

on 10/9/18